Search
Oxandrolone
go.drugbank.com/drugs/DB00621ApprovedInvestigationalA synthetic hormone with anabolic and androgenic properties.
R-851
go.drugbank.com/drugs/DB05747ExperimentalR-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. … It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually transmitted virus that causes most cases of cervical cancer.
Rufloxacin
go.drugbank.com/drugs/DB13772InvestigationalRufloxacin is a quinolone antibiotic.[A31894]
Categories: Topoisomerase II InhibitorsSulfabenzamide
go.drugbank.com/drugs/DB09355ApprovedWithdrawnSulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.
Synonyms: N-Benzoylsulfanilamide, N-SulfanilylbenzamideAIT-034
go.drugbank.com/drugs/DB06106ExperimentalAIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do … There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.
ATL-104
go.drugbank.com/drugs/DB05670InvestigationalATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
RTN-001
go.drugbank.com/drugs/DB05615InvestigationalSLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.